Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PEPD | P12955 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116344 | 0.93 | ACE (0.47) | OPRM1F2ACENTSR2NTSR1 | |
| SCHEMBL29380256 | 0.90 | OPRM1 (0.46) | OPRM1F2ACENTSR2NTSR1 | |
| SCHEMBL31114414 | 0.89 | ACE (0.53) | OPRM1F2ACEDPP4DPP7 | |
| SCHEMBL30292653 | 0.89 | ACE (0.47) | OPRM1F2ACEKDM4EREN | |
| SCHEMBL30116354 | 0.89 | ACE (0.47) | OPRM1F2ACEKDM4EREN | |
| SCHEMBL29379729 | 0.89 | ACE (0.47) | OPRM1F2ACEDPP4DPP7 | |
| SCHEMBL29721144 | 0.87 | ACE (0.52) | F2ACEDPP4DPP7DPP8 | |
| SCHEMBL31268702 | 0.87 | ACE (0.55) | OPRM1F2ACEDPP4DPP7 | |
| SCHEMBL31268656 | 0.87 | ACE (0.55) | OPRM1F2ACEDPP4DPP7 | |
| SCHEMBL30011765 | 0.87 | CAPN1 (0.49) | F2ACENTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293512-A1 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | HANMI PHARM. CO., LTD. (KR) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293512-A1 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | GLP1R, GIPR, GCGR | OPRM1 1955/4885F2 4445/4885ACE 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.